title: Subjects with impaired fasting glucose: evolution in a period of 6 years.
abstract: OBJECTIVE
  To study the evolution of impaired fasting glucose (IFG), considering glucose and HbA1c levels and risk factors associated, in a period of 6 years.
  
  
  METHODS
  We studied 94 subjects with impaired fasting glucose (IFG) that were diagnosed in 2005 and followed up to 2012. Glucose and HbA1c levels were determined. A descriptive analysis of contingence charts was performed in order to study the evolution in the development of type-2 diabetes mellitus (T2DM).
  
  
  RESULTS
  Twenty-eight of ninety-four subjects became T2DM; 51/94 remained with IFG; and 20/94 presented normal fasting glucose. From the 28 diabetic subjects, 9 had already developed diabetes and were under treatment with oral hypoglycemic agents; 5 were diagnosed with plasma glucose < 126 mg/dL, but with HbA1c over 6.5%. In those who developed diabetes, 15/28 had a family history of T2DM in first relative degree. Also, diabetic subjects had a BMI significantly higher than nodiabetics (t test: P < 0.01). The individuals that in 2005 had the highest BMI are those who currently have diabetes.
  
  
  CONCLUSIONS
  The IFG constitutes a condition of high risk of developing T2DM in a few years, especially over 110 mg/dL and in obesity patients.
authors.affiliation: Programa de Investigación de Excelencia Interdisciplinaria en Envejecimiento Saludable (PIEI-ES), Departamento de Bioquímica Clínica e Inmunohematología, Facultad de Ciencias de la Salud, Universidad de Talca, 3465548 Talca, Chile.
authors.forename: E
authors.initials: E
authors.lastname: Leiva
authors.affiliation: Facultad de Medicina, Universidad Católica del Maule, Avenida San Miguel 3605, 3480112 Talca, Chile.
authors.forename: V
authors.initials: V
authors.lastname: Mujica
authors.affiliation: Programa de Investigación de Excelencia Interdisciplinaria en Envejecimiento Saludable (PIEI-ES), Departamento de Bioquímica Clínica e Inmunohematología, Facultad de Ciencias de la Salud, Universidad de Talca, 3465548 Talca, Chile.
authors.forename: R
authors.initials: R
authors.lastname: Orrego
authors.affiliation: Programa de Investigación de Excelencia Interdisciplinaria en Envejecimiento Saludable (PIEI-ES), Departamento de Bioquímica Clínica e Inmunohematología, Facultad de Ciencias de la Salud, Universidad de Talca, 3465548 Talca, Chile.
authors.forename: S
authors.initials: S
authors.lastname: Wehinger
authors.affiliation: Programa de Investigación de Excelencia Interdisciplinaria en Envejecimiento Saludable (PIEI-ES), Instituto de Matemáticas y Física, Universidad de Talca, Chile 2 Norte 685, 3465548 Talca, Chile.
authors.forename: A
authors.initials: A
authors.lastname: Soto
authors.affiliation: Programa de Investigación de Excelencia Interdisciplinaria en Envejecimiento Saludable (PIEI-ES), Instituto de Matemáticas y Física, Universidad de Talca, Chile 2 Norte 685, 3465548 Talca, Chile.
authors.forename: G
authors.initials: G
authors.lastname: Icaza
authors.affiliation: Programa de Investigación de Excelencia Interdisciplinaria en Envejecimiento Saludable (PIEI-ES), Departamento de Bioquímica Clínica e Inmunohematología, Facultad de Ciencias de la Salud, Universidad de Talca, 3465548 Talca, Chile.
authors.forename: M
authors.initials: M
authors.lastname: Vásquez
authors.affiliation: Programa de Investigación de Excelencia Interdisciplinaria en Envejecimiento Saludable (PIEI-ES), Departamento de Bioquímica Clínica e Inmunohematología, Facultad de Ciencias de la Salud, Universidad de Talca, 3465548 Talca, Chile.
authors.forename: L
authors.initials: L
authors.lastname: Díaz
authors.affiliation: Laboratorio de Micronutrientes, INTA, Universidad de Chile, El Líbano 5524, Macul, 7830490 Santiago, Chile.
authors.forename: M
authors.initials: M
authors.lastname: Andrews
authors.affiliation: Laboratorio de Micronutrientes, INTA, Universidad de Chile, El Líbano 5524, Macul, 7830490 Santiago, Chile.
authors.forename: M
authors.initials: M
authors.lastname: Arredondo
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism*; D015992:Body Mass Index; D002677:Chile / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics; D018450:Disease Progression; D005215:Fasting / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D044882:Glucose Metabolism Disorders / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000175:diagnosis / Q000453:epidemiology; D010375:Pedigree; D012307:Risk Factors; D013997:Time Factors
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human